

#3  
7-10-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1c530 U.S. PTO  
09/528644  
03/20/00

In re Application of: Thim et al.

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: March 20, 2000

Examiner: To Be Assigned

For: Human Spasmolytic Polypeptide in Glycosylated Form

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants cited herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references was filed in application serial no. 08/491,976 filed on August 2, 1995 the benefit of which is claimed under 35 U.S.C. 120.


The references are as follows:

1. Abstract - Thim et al. Biochim Biophys Acta (Netherlands) 827: (3) p. 410-8 (1985).
2. Tomasetto et al., The EMBO Journal Vol. 9, No. 2 pp 407-414 (1990).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: March 20, 2000

  
\_\_\_\_\_  
Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123